Hansa Biopharma AB (publ) (HNSA.ST)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Renee Aguiar-Lucander | Chief Executive Officer | -- | -- | 1962 |
| Mr. C. Evan Ballantyne | CFO & Senior VP | -- | -- | 1960 |
| Ms. Eva-Maria Joed | Vice President of Finance & Administration | -- | -- | 1969 |
| Mr. Klaus Sindahl | VP & Head of Investor Relations | -- | -- | -- |
| Ms. Anne Säfström Lanner | Senior VP & Chief Human Resources Officer | -- | -- | 1969 |
| Mr. Emanuel Björne | VP & Head of Business Development | -- | -- | 1973 |
| Dr. Lena Winstedt | Head of Science | -- | -- | 1969 |
| Ms. Vincenza Nigro M.B.A. | VP & Head of Medical Affairs | -- | -- | -- |
| Dr. Magnus Korsgren | VP & Head of Research and Development | -- | -- | 1969 |
| Dr. Hitto Kaufmann Ph.D. | Senior VP, Chief R&D Officer | -- | -- | 1970 |
Hansa Biopharma AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 138
Description
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Corporate Governance
Upcoming Events
July 17, 2025 at 10:59 AM UTC
Hansa Biopharma AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available